NASDAQ : CYTK

Cytokinetics, Incorporated

$80.62 USD

-$0.12 (-0.15%)

Volume
1.66M
Average Volume
2.63M
Market Capitalization
$10.03B
P/E Ratio
-11.80
Dividend Yield
0.00%
Price Target
$108.00
Year High
$88.31
Year Low
$32.89
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$4.21
Company Overview

NASDAQ

Robert I. Blum

Biotechnology

Healthcare

CYTK

673

US

USD

https://www.cytokinetics.com

650 624 3000

23282W605

0001061983

Liquidity Metrics

-1.56

4.21

4.21

0.65

0.00

Sales & Valuation

$88.04M

94.80

-12.02

-18.28

-4.45

Profitability

-$6.54

-$784.96M

-784.02%

-784.02%

139.66%

-65.15%

P/E Metrics

-11.80

0.44

0.44

Analyst Price Target & Rating

$108.00

$140.00

$84.00

Sell

2/5

35 Analysts

-25.35%

Financial Health Scores

-2.44

3/9

$640.28M

$1.27B

$2.1B

-$745.69M

Key Metrics (TTM)

$11.21B

105.90

-15.25

4.21

139.66%

-56.16%

-8.34%

-5.46%

-854 days

Company Executives
Name Title
Fady Ibraham Malik FACC Executive Vice President of Research & Development
Holly Laughlin Vice President of Accounting & Corporate Controller
James A. Spudich Co-Founder & Member of Scientific Advisory Board
James H. Sabry Co-Founder & Chairman of Scientific Advisory Board
Jeff Lotz Vice President of Sales & Operations
Steven Cook Senior Vice President of Global Supply Chain Operations & Technical Operations
Sung H. Lee EVP & CFO
Andrew Callos Executive Vice President & Chief Commercial Officer
Jeffrey J. Hessekiel Executive Vice President, Chief Legal & Administrative Officer
Robert I. Blum Chief Executive Officer, President & Director
Poll Results

No votes yet today — be the first to share your view!

About Cytokinetics, Incorporated (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with he ... art failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Cytokinetics: Label Expansion Can Turn MYQORZO Into An HCM Franchise

2026-07-22 13:39:48

Cytokinetics (CYTK) is positioned to expand MYQORZO across the entire HCM continuum, not just as a late-stage competitor to Camzyos. Initial MYQORZO launch metrics—rapid market access, >30% new-to-brand share, and strong prescriber uptake—signal robust commercial traction beyond headline Q1 revenue. MAPLE-HCM and ACACIA-HCM trials support earlier use and a potential doubling of the addressable market via non-obstructive HCM, driving CYTK's long-term value.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-07-17 16:00:00

SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 15, 2026 it granted stock options to purchase an aggregate of 21,220 shares of common stock and 14,067 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 10 employees, whose employment commenced in June and July 2026 as a material inducement to their employment.

All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy

2026-07-15 13:01:05

Cytokinetics (CYTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet

2026-07-15 10:55:18

The mean of analysts' price targets for Cytokinetics (CYTK) points to a 30.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%

2026-07-14 17:20:21

The insider liquidated 7,500 shares at a weighted average price of $82.02. The disposition represented 2% of the executive's total reported equity holdings.

Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?

2026-07-10 15:11:07

CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.

iShares Russell 2000 Value vs. Morningstar Small Cap: Which ETF Suits Your Portfolio Best?

2026-07-07 07:40:01

IWN delivered a 37.4% one-year return but carries higher fees, while ISCV offers a 0.06% expense ratio and stronger dividend yield of 1.9%.

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

2026-07-07 07:30:00

Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

Frequently Asked Questions

What is the current Cytokinetics, Incorporated (CYTK) stock price?

Cytokinetics, Incorporated(NASDAQ:CYTK) stock price is $80.62 in the last trading session. During the trading session, CYTK stock reached the peak price of $88.31 while $32.89 was the lowest point it dropped to. The percentage change in CYTK stock occurred in the recent session was --0.15% while the dollar amount for the price change in CYTK stock was -$0.12.

CYTK's industry and sector of operation?

The NASDAQ listed CYTK is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of CYTK?

Fady Ibraham Malik FACC | Executive Vice President of Research & Development
Holly Laughlin | Vice President of Accounting & Corporate Controller
James A. Spudich | Co-Founder & Member of Scientific Advisory Board
James H. Sabry | Co-Founder & Chairman of Scientific Advisory Board
Jeff Lotz | Vice President of Sales & Operations

How many employees does CYTK have?

Number of CYTK employees currently stands at 673. CYTK operates from 350 Oyster Point Boulevard, South San Francisco, CA 94080, US.

Link for CYTK official website?

Official Website of CYTK is: https://www.cytokinetics.com

How do I contact CYTK?

CYTK could be contacted at phone #650 624 3000 and can also be accessed through its website. CYTK operates from 350 Oyster Point Boulevard, South San Francisco, CA 94080, US.

How many shares of CYTK are traded daily?

The average number of CYTK shares traded daily for last 3 months was 2.63M.

What is the market cap of CYTK currently?

The market value of CYTK currently stands at $10.03B with its latest stock price at $80.62